Welcome to our dedicated page for Purple Biotech SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Purple Biotech Ltd. (PPBT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Purple Biotech files its annual report on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with registration statements on Forms F-1, F-3 and S-8, outline the company’s clinical-stage oncology strategy, financing activities, and corporate actions.
Through its Form 6-K reports, Purple Biotech furnishes press releases and corporate presentations that describe its oncology pipeline, including the CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219. Filings reference milestones such as manufacturing achievements for IM1240, preclinical and clinical data updates, European patent developments for NT219 combinations, and collaborations with academic institutions. They also include financial results, at-the-market offering agreements, and details of public offerings of American Depositary Shares and warrants.
Investors use Purple Biotech’s SEC filings to review quarterly and interim financial information furnished on Form 6-K, as well as capital markets transactions such as shelf registrations on Form F-3 and follow-on offerings. The filings also document corporate governance events, including notices and results of shareholder meetings, and incorporate certain reports by reference into existing registration statements.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on pipeline progress, financing terms, and listing compliance matters. Users can follow new 6-K submissions in near real time as they are posted to EDGAR, and then drill into specific exhibits such as press releases or corporate presentations for more detail.
For those researching PPBT, this page serves as a central location to review Purple Biotech’s official SEC communications related to its clinical programs, financial position, and securities offerings, all organized chronologically with concise AI-generated overviews.
PURPLE BIOTECH LTD. Chief Executive Officer Gil Efron reported his initial ownership, showing direct holdings of 15,750,000 Ordinary Shares. This includes 12,375,000 unvested restricted stock units that vest over time and are settled in Ordinary Shares, which may be represented by American Depositary Shares, each currently equal to 2,000 Ordinary Shares.
He also holds stock options to purchase 1,500,000 Ordinary Shares at $0.095054688 per share expiring on May 23, 2027; 3,750,000 Ordinary Shares at $0.0765625 per share expiring on July 11, 2027; and 13,500,000 Ordinary Shares at $0.00309375 per share expiring on October 21, 2030, with 1,125,000 already vested and the remaining 12,375,000 vesting in equal quarterly installments until October 21, 2028.
PURPLE BIOTECH LTD. Chief Financial Officer Shai S. Lankry has updated his reported equity holdings. The filing shows stock options to purchase 3,000,000 ordinary shares under one grant and 3,550,000 ordinary shares under another, all under the company’s 2016 Equity-Based Incentive Plan.
The options for 3,000,000 ordinary shares carry an exercise price of $0.01359375 per share and expire on April 29, 2030. The options for 3,550,000 ordinary shares have an exercise price of $0.00309375 per share and expire on October 21, 2030, with 295,833 shares already vested.
The holdings also include 3,254,167 unvested restricted stock units, each representing one ordinary share subject to time-based vesting and settled in ordinary shares. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing 2,000 ordinary shares.
PURPLE BIOTECH LTD. executive Michael Schickler filed an initial ownership report showing 9,254,472 Ordinary Shares, including 6,958,334 unvested restricted stock units that vest over time and settle in Ordinary Shares. He also holds several stock options over Ordinary Shares with exercise prices between $0.10828125 and $0.00309375 per share, expiring between April 2027 and October 2030, some already vested and others vesting in quarterly installments.
PURPLE BIOTECH LTD. director Shai S. Lankry filed an initial ownership report showing a sizable equity position. He holds 3,550,000 Ordinary Shares, including 3,254,167 unvested restricted stock units that settle in shares or ADSs. He also holds stock options to purchase 3,000,000 Ordinary Shares at an exercise price of $0.01359375 per share and options to purchase 3,550,000 Ordinary Shares at $0.00309375 per share, both vesting over several years and expiring in 2030.
Purple Biotech Ltd. filed a Form 6-K to furnish a press release announcing an AI-driven collaboration with Converge Bio to advance its next-generation tri-specific antibody platform. The partnership uses Converge Bio’s generative AI to design and optimize oncology-focused antibodies, aiming to speed discovery and improve molecule quality.
Purple Biotech plans to apply these AI insights to its CAPTN-3 platform of masked tri-specific antibodies that engage both T cells and NK cells, with lead candidates IM1240 and IM1305 in preclinical development. The company also highlights additional clinical-stage assets CM24 and NT219, whose further progress depends on partnering or investment.
Purple Biotech Ltd. provides an updated corporate presentation describing its immuno-oncology pipeline and financial position. The company highlights its CAPTN-3 tri-specific antibody platform, led by IM1240 for solid tumors, with GLP toxicology planned in Q3 2026, an IND submission in Q4 2026 and first-in-human Phase 1 initiation in Q1 2027.
Two additional clinical-stage assets, CM24 for pancreatic cancer and NT219 for recurrent/metastatic head and neck cancer, have Phase 2 data and are positioned for partnerships. The company reports cash of $9.5 million and a cash runway extending into the first half of 2027, with 930K shares outstanding as of December 31, 2025.
Purple Biotech Ltd., an Israel-based clinical-stage biotechnology company, files its Form 20-F annual report for the year ended December 31, 2025. The company reports cumulative losses of approximately $171 million since starting its pharmaceutical R&D activities and remains unprofitable.
Purple Biotech is developing a preclinical tri-specific antibodies platform, CAPTN-3, with lead candidates IM1240 and IM1305, plus two oncology candidates in clinical trials, CM24 and NT219. As of December 31, 2025, it had 1,858,911,801 ordinary shares outstanding and maintains American Depositary Shares listed on the NASDAQ Capital Market.
The report emphasizes significant risks: dependence on a limited pipeline, the need to raise substantial additional capital, reliance on third parties for manufacturing and clinical work, extensive regulatory uncertainty, and the possibility of NASDAQ delisting if listing requirements are not met.
PURPLE BIOTECH LTD. director Robert E. Gagnon filed a Form 3 disclosing his equity stake in the company. He reports 3,062,500 Ordinary Shares held directly, including 2,454,167 unvested restricted stock units that vest over time and settle in Ordinary Shares.
Gagnon also holds three stock option awards: options for 112,500 Ordinary Shares at an exercise price of $0.146765625 per share expiring on December 29, 2026; options for 300,000 Ordinary Shares at $0.059375 per share expiring on April 24, 2028; and options for 2,650,000 Ordinary Shares at $0.00309375 per share expiring on October 21, 2030. The filing states that the Ordinary Shares may be represented by American Depositary Shares, with each ADS currently equal to 2,000 Ordinary Shares. No purchases or sales are reported; this is an initial ownership disclosure.
Purple Biotech Ltd. reports that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement. Nasdaq’s Listing Qualifications Department confirmed that the company now meets Nasdaq Listing Rule 5550(a)(2) for continued listing.
To regain compliance, Purple Biotech’s American Depositary Shares maintained a minimum closing bid price of at least $1.00 per share for 10 consecutive business days, a condition achieved on March 13, 2026. The company continues to develop its next-generation immunotherapy platform, including lead candidates IM1240 and IM1305 and other oncology assets.
Purple Biotech Ltd. reported a much wider full-year 2025 net loss of $26.4 million, driven mainly by a $20.5 million non-cash impairment of its CM24 and NT219 programs as it shifts focus to its CAPTN-3 tri-specific antibody platform.
Adjusted operating loss improved to $6.7 million from $10.4 million in 2024, reflecting lower clinical trial spending, while research and development expenses fell to $3.7 million from $7.6 million. Cash, cash equivalents and deposits totaled about $9.5 million as of December 31, 2025, which the company expects to fund operations into 2027.
The lead CAPTN-3 candidate IM1240 achieved toxicology and manufacturing milestones, and IM1305 was named a development candidate. Separately, CEO Gil Efron will step down in August 2026 for health reasons, remaining on the board and leading corporate development while a search for a new CEO is underway.